ArticleEndocrinology, diabetes & metabolism case reports2026
Bilateral pheochromocytoma as a late presentation of neurofibromatosis type 1.
Article in Endocrinology, diabetes & metabolism case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Impact of Germline Multigene Sequencing in Pediatric Cohorts with a Wide Spectrum of Neoplasms.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: Neurofibromatosis type 1 (NF1) is an autosomal dominant condition predisposing to tumors, including pheochromocytomas and paragangliomas. Reported penetrance is close to 100%, but clinical presentation is highly variable. We present a case of a 79-year-old woman with an atypical and late presentation of NF1 with bilateral pheochromocytomas. She presented with long-standing abdominal pain. Her medical history included takotsubo cardiomyopathy and two episodes of intraoperative cardiogenic shock, 12 and 19 years before. A CT-scan revealed a 61 mm mass in the left adrenal gland (spontaneous density of 39 HU (hounsfield units)) and a 12 mm mass in the right adrenal gland (43 HU). The MIBG (metaiodobenzylguanidine) scan demonstrated high uptake in the left adrenal gland lesion. Urinary fractionated metanephrines were elevated. She underwent a left adrenalectomy, and pathology findings revealed a composite pheochromocytoma-ganglioneuroma. Genetic testing disclosed a pathogenic variant in the NF1 gene. After surgery, urinary fractionated metanephrines normalized but became elevated again one year later. She underwent a right adrenalectomy, and pathology confirmed a 'typical' pheochromocytoma. Other than bilateral pheochromocytoma, the patient had no other clinical manifestations of NF1, including café-au-lait macules or cutaneous neurofibromas. This case highlights the importance of offering genetic testing to all patients with pheochromocytoma, which may reveal cases of NF1 with subtler and atypical clinical presentation. Learning points: Genetic testing should be offered to all patients with pheochromocytoma. Bilateral pheochromocytomas should raise suspicion for an underlying genetic syndrome, even in elderly patients or those without a known family history. Some patients with neurofibromatosis type 1 (NF1) may have a later and subtler presentation, including isolated pheochromocytoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.